Similar Papers

Paper Title
Journal
Date
Author
Prognostic factor analysis of patients with unresectablelung squamous cell carcinoma
...
Zhonghua zhong liu za zhi [Chinese journal of oncology] | VOL. 43
, et. al. ...
23 May 2021
Influence of different drug delivery methods for Endostar combined with a gemcitabine/cisplatin regimen in locally advanced or metastatic lung squamous cell carcinoma: A retrospective observational study.
Difei Yao ... Ying Yuan
Medicine | VOL. 97
Difei Yao, et. al.Difei Yao ... Ying Yuan
01 Aug 2018
Real-world effectiveness of second-line Afatinib versus chemotherapy for the treatment of advanced lung squamous cell carcinoma in immunotherapy-na\xefve patients
You-Yi Chen ... Chun-Fu Chang
BMC Cancer | VOL. 21
You-Yi Chen, et. al.You-Yi Chen ... Chun-Fu Chang
15 Nov 2021
Paclitaxel liposome for injection (Lipusu) plus cisplatin versus gemcitabine plus cisplatin in the first-line treatment of locally advanced or metastatic lung squamous cell carcinoma: A multicenter, randomized, open-label, parallel controlled clinical study.
Jie Zhang ...
Cancer Communications | VOL. 42
Jie Zhang, et. al.Jie Zhang ...
26 Oct 2021
View more papers

More From: Journal of Thoracic Oncology

Paper Title
Journal
Date
Author
A Perspective on the MARS2 Trial
Eric Lim ... Harvey Pass
Journal of Thoracic Oncology | VOL. -
Eric Lim, et. al.Eric Lim ... Harvey Pass
01 Jan 2025
Meeting Announcements
-
Journal of Thoracic Oncology | VOL. -
--
01 Jan 2025
Phase 2 Open-Label Study of Sacituzumab Govitecan as Second-Line Therapy in Patients With Extensive-Stage Small Cell Lung Cancer: Results From TROPiCS-03
Afshin Dowlati ... Saiama N Waqar
Journal of Thoracic Oncology | VOL. -
Afshin Dowlati, et. al.Afshin Dowlati ... Saiama N Waqar
01 Jan 2025
Editorial Board
-
Journal of Thoracic Oncology | VOL. -
--
01 Jan 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.